MCID: RNL114
MIFTS: 59

Renal Cell Carcinoma, Nonpapillary

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Cancer diseases

Aliases & Classifications for Renal Cell Carcinoma, Nonpapillary

MalaCards integrated aliases for Renal Cell Carcinoma, Nonpapillary:

Name: Renal Cell Carcinoma, Nonpapillary 57 29 6
Renal Cell Carcinoma 57 38 12 76 53 75 37 15 73
Adenocarcinoma of Kidney 57 12 53 75
Hypernephroma 57 12 75
Rcc 57 12 75
Hereditary Clear Cell Renal Cell Carcinoma 59 73
Renal Carcinoma, Chromophobe, Somatic 57 13
Nonpapillary Renal Cell Carcinoma 12 15
Carcinoma, Renal Cell 44 40
Hereditary Clear Cell Renal Cell Adenocarcinoma 59
Renal Cell Carcinoma, Clear Cell, Somatic 57
Conventional Renal Cell Carcinoma 73
Carcinoma, Renal Cell, Nonpapillary 40
Renal Cell Carcinoma Non-Papillary 75
Conventional Renal Cell Carcinoma 75
Renal Cell Carcinoma, Somatic 57
Common Renal Cell Carcinoma 75
Clear Cell Renal Carcinoma 75
Renal Cell Adenocarcinoma 53
Carcinoma Renal Cell 55
Ccrcc 75
Crcc 75

Characteristics:

Orphanet epidemiological data:

59

HPO:

32
renal cell carcinoma, nonpapillary:
Inheritance sporadic


Classifications:

Orphanet: 59  
Rare renal diseases


External Ids:

OMIM 57 144700
Disease Ontology 12 DOID:0050387 DOID:4450
MeSH 44 D002292
NCIt 50 C9385
Orphanet 59 ORPHA422526
ICD10 via Orphanet 34 C64
KEGG 37 H00021
UMLS 73 C0007134

Summaries for Renal Cell Carcinoma, Nonpapillary

OMIM : 57 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most common documented genetic abnormalities (Kovacs et al., 1997). Malignant tumors are subclassified into common or conventional renal cell carcinoma (clear cell); papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and unclassified renal cell carcinoma. The common or conventional type accounts for about 75% of renal cell neoplasms and is characterized genetically by a highly specific deletion of chromosome 3p. Papillary renal cell carcinoma (see 605074) accounts for about 10% of renal cell tumors. Chromophobe renal cell carcinoma accounts for approximately 5% of renal cell neoplasms. Genetically, chromophobe RCC is characterized by a combination of loss of heterozygosity of chromosomes 1, 2, 6, 10, 13, 17, and 21 and hypodiploid DNA content. Collecting duct carcinoma accounts for about 1% of renal cell carcinoma. Renal cell carcinoma occurs nearly twice as often in men as in women; incidence in the United States is equivalent among whites and blacks. Cigarette smoking doubles the likelihood of renal cell carcinoma and contributes to as many as one-third of cases. Obesity is also a risk factor, particularly in women. Other risk factors include hypertension, unopposed estrogen therapy, and occupational exposure to petroleum products, heavy metals, or asbestos (summary by Motzer et al., 1996). (144700)

MalaCards based summary : Renal Cell Carcinoma, Nonpapillary, also known as renal cell carcinoma, is related to chromophobe renal cell carcinoma and clear cell renal cell carcinoma, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma, Nonpapillary is RNF139 (Ring Finger Protein 139), and among its related pathways/superpathways are Renal cell carcinoma and Transcriptional misregulation in cancer. The drugs Afinitor and Avastin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and lung, and related phenotype is renal cell carcinoma.

UniProtKB/Swiss-Prot : 75 Renal cell carcinoma: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Disease Ontology : 12 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

Wikipedia : 76 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Renal Cell Carcinoma, Nonpapillary

Diseases related to Renal Cell Carcinoma, Nonpapillary via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
# Related Disease Score Top Affiliating Genes
1 chromophobe renal cell carcinoma 34.3 FLCN HNF1A HNF1B
2 clear cell renal cell carcinoma 34.2 CYTOR FHIT FLCN HNF1A MALAT1 OGG1
3 kidney cancer 34.1 MALAT1 MIR141 MIR200C PVT1
4 hereditary conventional renal cell carcinoma 12.2
5 adamantinoma of long bones 11.4 CYTOR FHIT MALAT1 MIR141 MIR200C PANDAR
6 hereditary renal cell carcinoma 11.4 DIRC2 FHIT FLCN RNF139
7 cholangiocarcinoma 11.3 FHIT MALAT1 MIR141 OGG1 PANDAR
8 colorectal cancer 11.3 CYTOR FHIT FLCN MALAT1 MIR141 MIR200C
9 gastric cancer 11.3 CYTOR MALAT1 MIR141 MIR200C PANDAR PVT1
10 pancreatic ductal adenocarcinoma 11.2 MALAT1 MIR141 PVT1
11 renal cell carcinoma, papillary, 1 11.2
12 osteogenic sarcoma 11.2 MALAT1 PANDAR PVT1
13 clear cell papillary renal cell carcinoma 11.2 HNF1A VHL
14 gallbladder cancer 11.1 CYTOR FHIT MALAT1
15 birt-hogg-dube syndrome 11.1
16 cervical cancer 11.1 FHIT MALAT1 PANDAR PVT1
17 von hippel-lindau syndrome 11.0
18 bladder urothelial carcinoma 11.0 FHIT MALAT1 PVT1
19 thyroid carcinoma, papillary, with papillary renal neoplasia 10.9
20 chromophil renal cell carcinoma 10.9
21 hepatocellular carcinoma 10.9 CYTOR HNF1A MALAT1 MIR141 PANDAR PVT1
22 renal cell carcinoma, xp11-associated 10.9
23 malignant glioma 10.6 CYTOR MALAT1
24 oncocytoma 10.1
25 type i 10.1
26 hypoxia 10.1
27 hepatitis 10.0
28 horseshoe kidney 10.0
29 hepatitis b 9.9
30 renal oncocytoma 9.9
31 thrombosis 9.9
32 melanoma 9.9
33 endotheliitis 9.9
34 lung cancer 9.8
35 clear cell meningioma 9.8
36 collecting duct carcinoma 9.8
37 sarcomatoid renal cell carcinoma 9.8
38 tubulocystic renal cell carcinoma 9.8
39 acquired cystic disease-associated renal cell carcinoma 9.8
40 blue rubber bleb nevus 9.7
41 leukemia, chronic lymphocytic 9.7
42 alveolar soft part sarcoma 9.7
43 adenocarcinoma 9.7
44 papillary adenocarcinoma 9.7

Graphical network of the top 20 diseases related to Renal Cell Carcinoma, Nonpapillary:



Diseases related to Renal Cell Carcinoma, Nonpapillary

Symptoms & Phenotypes for Renal Cell Carcinoma, Nonpapillary

Clinical features from OMIM:

144700

Human phenotypes related to Renal Cell Carcinoma, Nonpapillary:

32
# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 32 HP:0005584

UMLS symptoms related to Renal Cell Carcinoma, Nonpapillary:


flank pain

Drugs & Therapeutics for Renal Cell Carcinoma, Nonpapillary

FDA approved drugs:

(show all 8)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Avastin 18 49 BEVACIZUMAB Genentech July 2009
3
Inlyta 18 49 AXITINIB Pfizer January 2012
4
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005
5
Proleukin 18 49 ALDESLEUKIN Chiron January 1998
6
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
7
Torisel 18 49 TEMSIROLIMUS Wyeth May 2007
8
Votrient 18 49 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Renal Cell Carcinoma, Nonpapillary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 500)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
2
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
3
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53123-88-9 5284616 6436030 46835353
6
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
7
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
8
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
9
Gemcitabine Approved Phase 4,Phase 2,Phase 1 95058-81-4 60750
10
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 284461-73-0 216239 406563
11
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 437-38-7 3345
13
Zoledronic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 118072-93-8 68740
14
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
15
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
16
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
17
Dopamine Approved Phase 4,Phase 2,Not Applicable 51-61-6, 62-31-7 681
18
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 50-02-2 5743
20
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
21
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
22
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
24
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-67-6 938
25
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 98-92-0 936
26
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
27 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 interferons Phase 4,Phase 3,Phase 2,Phase 1
42 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Neurotransmitter Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 1
47 HIV Protease Inhibitors Phase 4,Phase 2,Phase 1
48 Hormone Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
49 Hormones Phase 4,Phase 2,Phase 1,Early Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1562)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
3 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
4 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
5 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
6 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
7 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
8 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Completed NCT01266837 Phase 4 Everolimus
9 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
10 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
11 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
12 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
13 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
14 Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma Recruiting NCT02399124 Phase 4
15 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. Recruiting NCT01206764 Phase 4 RAD001
16 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
17 Effects of Anesthesia on Immunity in Cancer Recruiting NCT03514550 Phase 4 Propofol;Sevoflurane
18 Study of Nivolumab for Advanced Cancers in India Recruiting NCT03444766 Phase 4 Nivolumab
19 QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery Recruiting NCT03339284 Phase 4 Dexamethasone sodium phosphate;Ropivacaine Hydrocloride;Sodium Chloride 9mg/mL
20 Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy Recruiting NCT03323021 Phase 4
21 Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy Recruiting NCT03571490 Phase 4 Ropivacaine;Saline
22 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
23 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
24 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4 Nivolumab
25 Efficacy of IV Acetaminophen Versus Oral Acetaminophen Not yet recruiting NCT03365622 Phase 4 acetaminophen;Acetaminophen;Placebos;Placebo Oral Tablet
26 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
27 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
28 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
29 Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
30 Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
31 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Unknown status NCT00869011 Phase 3
32 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
33 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
34 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
35 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
36 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
37 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
38 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
39 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
40 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
41 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
42 Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) Completed NCT00478114 Phase 3 sorafenib
43 IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma Completed NCT01265901 Phase 3 Sunitinib;Cyclophosphamide;IMA901
44 Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Completed NCT01223027 Phase 3 Dovitinib;Sorafenib
45 Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer Completed NCT00033904 Phase 3 autologous human tumor-derived HSPPC-96
46 Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) Completed NCT01613846 Phase 3 Sorafenib+Pazopanib;Pazopanib+Sorafenib
47 A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma Completed NCT01030783 Phase 3 tivozanib (AV-951);Sorafenib
48 ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma Completed NCT00420888 Phase 2, Phase 3 ABR-217620/naptumomab estafenatox;IFN-alpha
49 Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma Completed NCT02030717 Phase 2, Phase 3 klonidin;epidural anesthesia
50 Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer Completed NCT00003126 Phase 3 Interleukin-2

Search NIH Clinical Center for Renal Cell Carcinoma, Nonpapillary

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoma, renal cell

Genetic Tests for Renal Cell Carcinoma, Nonpapillary

Genetic tests related to Renal Cell Carcinoma, Nonpapillary:

# Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Nonpapillary 29 DIRC2 FLCN HNF1A HNF1B OGG1 RNF139 VHL

Anatomical Context for Renal Cell Carcinoma, Nonpapillary

MalaCards organs/tissues related to Renal Cell Carcinoma, Nonpapillary:

41
Kidney, Endothelial, Lung, Bone, T Cells, Brain, Prostate

Publications for Renal Cell Carcinoma, Nonpapillary

Articles related to Renal Cell Carcinoma, Nonpapillary:

(show top 50) (show all 5887)
# Title Authors Year
1
Expression of vitamin D receptor in clear cell papillary renal cell carcinoma. ( 29966830 )
2018
2
Diagnostic Accuracy of Unenhanced CT Analysis to Differentiate Low-Grade From High-Grade Chromophobe Renal Cell Carcinoma. ( 29547054 )
2018
3
Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female. ( 29409504 )
2018
4
Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability. ( 29482572 )
2018
5
Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. ( 29974846 )
2018
6
Next-Generation Sequencing to Detect Deletion of RB1 and ERBB4 Genes in Chromophobe Renal Cell Carcinoma: A Potential Role in Distinguishing Chromophobe Renal Cell Carcinoma from Renal Oncocytoma. ( 29353061 )
2018
7
Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by<sup>18</sup>F-FDG PET/CT: a Case Report and Review of Literature. ( 29354391 )
2018
8
Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling. ( 29396852 )
2018
9
Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma? ( 29970253 )
2018
10
Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma. ( 29963157 )
2018
11
Biallelic <i>TSC2</i> Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus. ( 29632054 )
2018
12
Fine-needle aspiration of tubulocystic renal cell carcinoma. ( 29624918 )
2018
13
Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma. ( 28676023 )
2018
14
Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor. ( 29920137 )
2018
15
Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms. ( 29056573 )
2018
16
Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. ( 29410489 )
2018
17
Emerging entities in renal cell neoplasia: thyroid-like follicular renal cell carcinoma and multifocal oncocytoma-like tumours associated with oncocytosis. ( 29132724 )
2018
18
Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma. ( 29429069 )
2018
19
Influence of Contrast Administration on Computed Tomography-Based Analysis of Visceral Adipose and Skeletal Muscle Tissue in Clear Cell Renal Cell Carcinoma. ( 29350403 )
2018
20
Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10-year retrospective study from two institutions. ( 29963177 )
2018
21
Clear cell renal cell carcinoma: identifying PTEN expression on multiphasic MDCT. ( 29946925 )
2018
22
Sarcomatoid renal cell carcinoma: Biology and treatment advances. ( 29306556 )
2018
23
Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentary. ( 29742094 )
2018
24
Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma. ( 29661724 )
2018
25
Acquired Cystic Disease-associated Renal Cell Carcinoma (ACD-RCC): A Multiinstitutional Study of 40 Cases With Clinical Follow-up. ( 29851703 )
2018
26
Genetic and metabolic hallmarks of clear cell renal cell carcinoma. ( 29959988 )
2018
27
Case - Laparoscopic transperitoneal partial nephrectomy of T3a renal cell carcinoma within a horseshoe kidney. ( 29405905 )
2018
28
SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-I_B signaling. ( 29183723 )
2018
29
Correction to: Reassessing the clinical spectrum associated with Hereditary Leiomyomatosis and Renal Cell Carcinoma syndrome in French FH mutation carriers. ( 29655270 )
2018
30
A back-to-back tumor composed of papillary renal cell carcinoma and oncocytoma treated by laparoscopic partial nephrectomy: a case report. ( 29779490 )
2018
31
Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. ( 29357836 )
2018
32
Leukemia Inhibitory Factor Receptor Suppresses the Metastasis of Clear Cell Renal Cell Carcinoma Through Negative Regulation of the Yes-Associated Protein. ( 29902078 )
2018
33
Oral metastasis of renal cell carcinoma mimicking recurrence of excised malignant myoepithelioma: A case report. ( 29896402 )
2018
34
Chromophobe Renal Cell Carcinoma With Retrograde Venous Invasion and Gain of Chromosome 21: Potential Harbingers of Aggressive Clinical Behavior. ( 29560759 )
2018
35
Synchronous ipsilateral renal cell carcinoma and transitional cell carcinoma of the renal pelvic with complete remission of TCC after neoadjuvant chemotherapy. ( 29888183 )
2018
36
Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. ( 29680948 )
2018
37
FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma. ( 29368368 )
2018
38
Tubulocystic renal cell carcinoma: a review of literature focused on radiological findings for differential diagnosis. ( 29796844 )
2018
39
LINC00037 Inhibits Proliferation of Renal Cell Carcinoma Cells in an Epidermal Growth Factor Receptor-Dependent Way. ( 29393141 )
2018
40
Molecular Characterization and Putative Pathogenic Pathways of Tuberous Sclerosis Complex-Associated Renal Cell Carcinoma. ( 29925043 )
2018
41
Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. ( 29368125 )
2018
42
Takotsubo syndrome induced by malignant pheochromocytoma in a patient with type 2 papillary renal cell carcinoma - a case report. ( 29785166 )
2018
43
Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma. ( 29944950 )
2018
44
DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NFa89I_B pathway. ( 29901172 )
2018
45
Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. ( 29910061 )
2018
46
Evaluation and prognostic significance of manganese superoxide dismutase in clear cell renal cell carcinoma. ( 29935195 )
2018
47
Long noncoding RNA lung cancer associated transcript 1 promotes proliferation and invasion of clear cell renal cell carcinoma cells by negatively regulating miR-495-3p. ( 29932248 )
2018
48
Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma. ( 29752278 )
2018
49
Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma. ( 29426696 )
2018
50
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. ( 29877179 )
2018

Variations for Renal Cell Carcinoma, Nonpapillary

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

75
# Symbol AA change Variation ID SNP ID
1 FLCN p.Arg239Cys VAR_066026 rs78683075
2 SETD2 p.Asn1733Asp VAR_069812
3 SETD2 p.Ser1769Pro VAR_069813
4 VHL p.Leu163Pro VAR_034998 rs28940297

ClinVar genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 OGG1 NM_016821.2(OGG1): c.1043G> A (p.Gly348Glu) single nucleotide variant Likely benign rs41276495 GRCh37 Chromosome 3, 9807587: 9807587
2 OGG1 NM_016821.2(OGG1): c.1043G> A (p.Gly348Glu) single nucleotide variant Likely benign rs41276495 GRCh38 Chromosome 3, 9765903: 9765903

Cosmic variations for Renal Cell Carcinoma, Nonpapillary:

9
(show top 50) (show all 2581)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 49
2 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 3:124737785-124737785 49
3 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 49
4 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 49
5 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 49
6 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 9:123020414-123020414 49
7 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 49
8 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 11:118497991-118497991 49
9 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 49
10 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 10:127023241-127023241 49
11 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 49
12 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 6:44419552-44419552 49
13 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 11:110586276-110586276 49
14 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma c.563G>C p.G188A 23:123886225-123886225 44
15 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma c.353T>C p.L118P 3:10146526-10146526 44
16 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma c.292T>G p.Y98D 3:10142139-10142139 44
17 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma c.245G>C p.R82P 3:10142092-10142092 44
18 COSM6957851 TSC2 kidney,NS,carcinoma,renal cell carcinoma c.541G>A p.V181M 16:2055461-2055461 44
19 COSM6942356 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.2287C>T p.Q763* 9:132902709-132902709 44
20 COSM6963117 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.1001C>A p.S334* 9:132911481-132911481 44
21 COSM29770 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.508+1G>T p.? 9:132923347-132923347 44
22 COSM10656 TP53 kidney,NS,carcinoma,renal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 44
23 COSM45243 TP53 kidney,NS,carcinoma,renal cell carcinoma c.374C>G p.T125R 17:7675995-7675995 44
24 COSM44310 TP53 kidney,NS,carcinoma,renal cell carcinoma c.738G>A p.M246I 17:7674225-7674225 44
25 COSM6922197 TP53 kidney,NS,carcinoma,renal cell carcinoma c.97-2A>C p.? 17:7676274-7676274 44
26 COSM45135 TP53 kidney,NS,carcinoma,renal cell carcinoma c.673-1G>T p.? 17:7674291-7674291 44
27 COSM6929752 TBX3 kidney,NS,carcinoma,renal cell carcinoma c.510G>T p.W170C 12:114681026-114681026 44
28 COSM6979493 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2096+1G>A p.? 23:124065947-124065947 44
29 COSM6975582 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.1348A>T p.R450* 23:124057909-124057909 44
30 COSM6023628 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2860C>T p.R954C 23:124081464-124081464 44
31 COSM6963119 SPOP kidney,NS,carcinoma,renal cell carcinoma c.265T>G p.L89V 17:49619321-49619321 44
32 COSM6964939 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.987-2A>T p.? 22:23833570-23833570 44
33 COSM989 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.1130G>A p.R377H 22:23834152-23834152 44
34 COSM1266238 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma c.3575G>A p.R1192H 19:11033318-11033318 44
35 COSM6947611 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.863C>A p.S288* 3:47122264-47122264 44
36 COSM6975580 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.4736C>G p.S1579* 3:47062211-47062211 44
37 COSM4118007 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.3266G>A p.R1089Q 3:47106061-47106061 44
38 COSM4794860 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.5922+1G>A p.? 3:47019759-47019759 44
39 COSM6925125 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.179C>A p.S60* 23:47169476-47169476 44
40 COSM6922201 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.299G>C p.G100A 23:47171125-47171125 44
41 COSM6947629 PTCH1 kidney,NS,carcinoma,renal cell carcinoma c.3616C>T p.R1206C 9:95449257-95449257 44
42 COSM6927541 PRKN kidney,NS,carcinoma,renal cell carcinoma c.629T>G p.F210C 6:161973407-161973407 44
43 COSM6913448 POLE kidney,NS,carcinoma,renal cell carcinoma c.4735C>T p.R1579C 12:132642723-132642723 44
44 COSM6972882 PMS1 kidney,NS,carcinoma,renal cell carcinoma c.572T>A p.V191E 2:189818170-189818170 44
45 COSM6923488 PIM1 kidney,NS,carcinoma,renal cell carcinoma c.101T>A p.L34Q 6:37170791-37170791 44
46 COSM6969911 PIK3CG kidney,NS,carcinoma,renal cell carcinoma c.2039T>A p.F680Y 7:106872580-106872580 44
47 COSM763 PIK3CA kidney,NS,carcinoma,renal cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 44
48 COSM6921803 PIK3C2G kidney,NS,carcinoma,renal cell carcinoma c.3493T>C p.F1165L 12:18562728-18562728 44
49 COSM6922195 PIK3C2G kidney,NS,carcinoma,renal cell carcinoma c.1986G>C p.Q662H 12:18391235-18391235 44
50 COSM6918100 PBRM1 kidney,NS,carcinoma,renal cell carcinoma c.1183A>C p.S395R 3:52634720-52634720 44

Copy number variations for Renal Cell Carcinoma, Nonpapillary from CNVD:

7 (show top 50) (show all 1298)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14830 1 1104523 1105523 Gain Renal cell carcinoma
2 16766 1 13658511 13659511 Gain Renal cell carcinoma
3 16770 1 13703176 13704176 Loss Renal cell carcinoma
4 16773 1 13722829 13723829 Gain Renal cell carcinoma
5 19216 1 14925199 15393109 Loss Renal cell carcinoma
6 24428 1 180300000 185800000 Copy number Renal cell carcinoma
7 26325 1 199103044 199104044 Gain Renal cell carcinoma
8 27335 1 207179162 207180162 Gain Renal cell carcinoma
9 27861 1 214500000 224100000 Gain Renal cell carcinoma
10 30088 1 24000000 26000000 Loss Renal cell carcinoma
11 31042 1 24862824 24867531 Loss RCAN3 Renal cell carcinoma
12 31527 1 28000000 30200000 Loss Renal cell carcinoma
13 33893 1 5000000 7000000 Loss Renal cell carcinoma
14 42189 10 3000000 17300000 Copy number Renal cell carcinoma
15 42932 10 42300000 52900000 Copy number Renal cell carcinoma
16 49432 11 106916419 134173875 Loss Renal cell carcinoma
17 49705 11 110400000 121200000 Copy number Renal cell carcinoma
18 51840 11 13182721 13183721 Gain Renal cell carcinoma
19 51843 11 13184856 13185856 Loss Renal cell carcinoma
20 52861 11 21000000 57000000 Gain Renal cell carcinoma
21 53056 11 23642584 23643584 Gain Renal cell carcinoma
22 53595 11 31000000 43500000 Copy number Renal cell carcinoma
23 53953 11 35317771 35318771 Gain Renal cell carcinoma
24 60490 11 87000000 107000000 Gain Renal cell carcinoma
25 64438 12 12800000 14800000 Copy number Renal cell carcinoma
26 67031 12 35000000 69000000 Gain Renal cell carcinoma
27 67043 12 35400000 132349534 Gain Renal cell carcinoma
28 69398 12 54900000 58100000 Copy number Renal cell carcinoma
29 72532 12 82000000 100000000 Gain Renal cell carcinoma
30 75379 13 19500000 23300000 Loss Renal cell carcinoma
31 75593 13 21548578 21635655 Copy number Renal cell carcinoma
32 82801 14 15600000 106368585 Copy number Renal cell carcinoma
33 82818 14 15600000 106368585 Loss Renal cell carcinoma
34 83187 14 19387587 106241517 Loss Renal cell carcinoma
35 85229 14 41000000 48000000 Gain Renal cell carcinoma
36 87551 14 74550219 74587988 Loss MLH3 Renal cell carcinoma
37 88249 14 88692268 89155247 Loss FOXN3 Renal cell carcinoma
38 88312 14 89800000 91900000 Copy number Renal cell carcinoma
39 89170 15 100153615 100154615 Gain Renal cell carcinoma
40 90158 15 20233523 20234523 Gain Renal cell carcinoma
41 90187 15 20359182 20360182 Gain Renal cell carcinoma
42 90188 15 20359229 20360229 Gain Renal cell carcinoma
43 90209 15 20439260 20440260 Loss Renal cell carcinoma
44 90210 15 20442152 20442452 Loss Renal cell carcinoma
45 90214 15 20449913 20450913 Gain Renal cell carcinoma
46 90215 15 20450115 20451115 Loss Renal cell carcinoma
47 90218 15 20535877 20536877 Loss Renal cell carcinoma
48 90224 15 20611271 20612271 Loss Renal cell carcinoma
49 90229 15 20643792 20644792 Loss Renal cell carcinoma
50 90232 15 20666179 20666479 Loss Renal cell carcinoma

Expression for Renal Cell Carcinoma, Nonpapillary

Search GEO for disease gene expression data for Renal Cell Carcinoma, Nonpapillary.

Pathways for Renal Cell Carcinoma, Nonpapillary

Pathways related to Renal Cell Carcinoma, Nonpapillary according to KEGG:

37
# Name Kegg Source Accession
1 Renal cell carcinoma hsa05211
2 Transcriptional misregulation in cancer hsa05202

GO Terms for Renal Cell Carcinoma, Nonpapillary

Biological processes related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of Wnt signaling pathway GO:0030111 9.26 HNF1A HNF1B
2 insulin secretion GO:0030073 9.16 HNF1A HNF1B
3 positive regulation of transcription initiation from RNA polymerase II promoter GO:0060261 8.96 HNF1A HNF1B
4 regulation of pronephros size GO:0035565 8.62 HNF1A HNF1B

Sources for Renal Cell Carcinoma, Nonpapillary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....